MBX Biosciences

MBX to present Obesity Portfolio updates at Obesity Day (10:30am ET) including initial Ph1 data for MBX 4291 (GLP‑1/GIP co‑agonist). Register here: ‌investors.mbxbio.com/news-events/ev…

MBX announces Q1 2026 earnings and the appointment of global biopharma commercial leader, Mark Soued, MBA as Chief Commercial Officer, as the Company advances its proprietary Precision Endocrine Peptides (PEPs)™ pipeline. investors.mbxbio.com/news-events/ne…

This #WorldHormoneDay, MBX joins @ESEndocrinology to spotlight the impact of hormone imbalances – from obesity to 400+ rare endocrine diseases including hypoparathyroidism. We’re advancing Precision Endocrine Peptides™ to address unmet needs. Learn more: mbxbio.com

MBX will host an in-person and virtual Obesity Day on Monday, May 11, 2026 at 10:30 a.m. ET to provide an update on its expanding obesity portfolio. Register here: lifescievents.com/event/hlg08k6

We’re #Hiring! At MBX, we’re looking for researchers and clinical & regulatory professionals to join our mission to improve care for rare endocrine and metabolic disorders. Explore our open roles: mbxbio.com/careers

This #WorldHealthDay, MBX supports the @WHO's call to #StandWithScience. With a focus on science-led innovation through our proprietary PEP™ Platform, we aim to transform the treatment landscape for endocrine and metabolic diseases. Learn more: mbxbio.com

This Women’s History Month, we want to thank all the talented and driven women that embody our mission, values and operating principles in support of our goal to improve the lives of people living with endocrine and metabolic disorders.

Today, we shared our Q4 and full-year 2025 financial results. View our highlights and upcoming milestones in the press release: investors.mbxbio.com/news-releases/…

Our CEO, @KentHawryluk, has been appointed to the Biotechnology Innovation Organization @IAmBiotech Board of Directors, where his deep experience building organizations and commitment to patients will support BIO’s mission to expand innovation and improve medicine access.

Tomorrow, our CEO, @KentHawryluk, and CMO, Sam Azoulay, MD, are meeting with investors at the @Jefferies Biotech on the Beach Summit and participating in a fireside chat at the @Barclays 28th Annual Global Healthcare Conference. Access the webcast: investors.mbxbio.com/news-releases/…

#NEWS: Welcome Karen Basbaum, MBA, as Chief Business Officer at MBX! Ms. Basbaum’s two decades of leadership in biopharma will be crucial as we advance our pipeline and pursue strategic opportunities to maximize the impact of our therapies for patients. investors.mbxbio.com/news-releases/…

#NEWS: Today, we announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the @US_FDA to discuss the overall Phase 3 trial design for our once-weekly investigational therapy for the treatment of chronic #hypoparathyroidism. investors.mbxbio.com/news-releases/…

Chief Human Resource Officer, Michelle Graham, took a moment to reflect on #EmployeeAppreciationDay and to thank all the exceptional individuals who are making an impact every day through their dedication, collaboration, and commitment to patients here at MBX.

Next week, our CEO, @KentHawryluk, and CMO, Sam Azoulay, MD, are participating in a fireside chat at the @CitizensBank Life Sciences Conference and meeting with investors at the @UBS Biotech Summit. Access the presentation webcast here: investors.mbxbio.com/news-releases/…

We’re joining @WorldObesity to raise awareness of the unmet needs of people living with obesity. We’re advancing new potential therapeutic options, with a growing obesity pipeline built on our PEP platform, designed for once-monthly dosing and improved tolerability.

Just like our handprints, every rare disease journey is unique – but combined, they represent a powerful symbol of unity, compassion, and awareness that amplifies the experiences of the 300 million people worldwide living with a rare disease. #RareDiseaseDay

Stay tuned for the presentation and fireside chat from our CEO, @KentHawryluk, and CMO, Salomon (Sam) Azoulay, MD, at next week’s TD Cowen 46th Annual Healthcare Conference. Access the webcast: investors.mbxbio.com/news-releases/…

We’ll be on the ground for four Miami conferences in March: @CitizensBank Life Sciences Conference, the @UBS Biotech Summit, the @Jefferies Biotech on the Beach Summit and the @Barclays 28th Annual Global Healthcare Conference. investors.mbxbio.com/news-releases/…

In recognition of #RareDiseaseDay, we are spotlighting #hypoparathyroidism – a rare endocrine condition requiring constant monitoring – for which we are developing a potential once-weekly investigational therapy. Learn more: #patient-stories" target="_blank" rel="nofollow noopener">mbxbio.com/patients/#pati…

Next week, our CEO, @KentHawryluk, and CMO, Sam Azoulay, MD, will participate in a fireside chat & 1x1s at the @Oppenheimer 36th Annual Healthcare Life Sciences Conference. Access the webcast here: investors.mbxbio.com/news-releases/…